Literature DB >> 18996348

HIV evades RNA interference directed at TAR by an indirect compensatory mechanism.

Joshua N Leonard1, Priya S Shah, John C Burnett, David V Schaffer.   

Abstract

HIV can rapidly evolve when placed under selective pressure, including immune surveillance or the administration of antiretroviral drugs. Typically, a variant protein allows HIV to directly evade the selective pressure. Similarly, HIV has escaped suppression by RNA interference (RNAi) directed against viral RNAs by acquiring mutations at the target region that circumvent RNAi-mediated inhibition while conserving necessary viral functions. However, when we directed RNAi against the viral TAR hairpin, which plays an indispensable role in viral transcription, resistant strains were recovered, but none carried a mutation at the target site. Instead, we isolated several strains carrying promoter mutations that indirectly compensated for the RNAi by upregulating viral transcription. Combining RNAi with the application of an antiviral drug blocked replication of such mutants. Evolutionary tuning of viral transcriptional regulation may serve as a general evasion mechanism that may be targeted to improve the efficacy of antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18996348      PMCID: PMC2742160          DOI: 10.1016/j.chom.2008.09.008

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  65 in total

1.  Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding.

Authors:  T Suzuki; A Kimura; R Nagai; M Horikoshi
Journal:  Genes Cells       Date:  2000-01       Impact factor: 1.891

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication.

Authors:  L Berthoux; C Péchoux; J L Darlix
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  A second post-transcriptional trans-activator gene required for HTLV-III replication.

Authors:  J Sodroski; W C Goh; C Rosen; A Dayton; E Terwilliger; W Haseltine
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

5.  Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat.

Authors:  M J Selby; E S Bain; P A Luciw; B M Peterlin
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

6.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells.

Authors:  Jenn-Yah Yu; Stacy L DeRuiter; David L Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

8.  Gene silencing in mammalian cells by preformed small RNA duplexes.

Authors:  Marianne Leirdal; Mouldy Sioud
Journal:  Biochem Biophys Res Commun       Date:  2002-07-19       Impact factor: 3.575

9.  The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.

Authors:  April J Schumacher; Guylaine Haché; Donna A Macduff; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

10.  Modulation of HIV-1 replication by RNA interference.

Authors:  Jean-Marc Jacque; Karine Triques; Mario Stevenson
Journal:  Nature       Date:  2002-06-26       Impact factor: 69.504

View more
  26 in total

1.  HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites.

Authors:  Priya S Shah; Nhung P Pham; David V Schaffer
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

Review 2.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

3.  Combinatorial latency reactivation for HIV-1 subtypes and variants.

Authors:  John C Burnett; Kwang-Il Lim; Arash Calafi; John J Rossi; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

4.  CRISPR-mediated Activation of Latent HIV-1 Expression.

Authors:  Prajit Limsirichai; Thomas Gaj; David V Schaffer
Journal:  Mol Ther       Date:  2015-11-26       Impact factor: 11.454

5.  An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells.

Authors:  Jae-Hyung Jang; James T Koerber; Jung-Suk Kim; Prashanth Asuri; Tandis Vazin; Melissa Bartel; Albert Keung; Inchan Kwon; Kook In Park; David V Schaffer
Journal:  Mol Ther       Date:  2011-01-11       Impact factor: 11.454

6.  The HIV-1 Tat protein has a versatile role in activating viral transcription.

Authors:  Atze T Das; Alex Harwig; Ben Berkhout
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 7.  Kinetic Modeling of Virus Growth in Cells.

Authors:  John Yin; Jacob Redovich
Journal:  Microbiol Mol Biol Rev       Date:  2018-03-28       Impact factor: 11.056

Review 8.  Novel HIV-1 therapeutics through targeting altered host cell pathways.

Authors:  William Coley; Kylene Kehn-Hall; Rachel Van Duyne; Fatah Kashanchi
Journal:  Expert Opin Biol Ther       Date:  2009-11       Impact factor: 4.388

9.  Development of a low bias method for characterizing viral populations using next generation sequencing technology.

Authors:  Stephanie M Willerth; Hélder A M Pedro; Lior Pachter; Laurent M Humeau; Adam P Arkin; David V Schaffer
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

Review 10.  Creating genetic resistance to HIV.

Authors:  John C Burnett; John A Zaia; John J Rossi
Journal:  Curr Opin Immunol       Date:  2012-09-15       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.